Skip to content

Advertisement

  • Poster presentation
  • Open Access

Immunotherapeutic potential of varicella vaccine in smoldering and cutaneous adult T-cell leukemia/lymphoma

Retrovirology201411 (Suppl 1) :P21

https://doi.org/10.1186/1742-4690-11-S1-P21

  • Published:

Keywords

  • Lymphoma
  • Partial Response
  • Skin Lesion
  • Promising Candidate
  • Herpes Zoster

There are several subtypes of HTLV-1-induced adult T-cell leukemia/lymphoma (ATLL): acute, lymphoma, chronic, and smoldering. Chronic and smoldering ATLL have a relatively good prognosis, even without treatment. However, these types can evolve to acute type ATLL, which has a poor prognosis. Previously we experienced some ATLL patients with improving skin involvements after suffering from herpes zoster and we reported that varicella-zoster virus could be capable of activating the immune system by the manifestation of active inflammation. We postulated that varicella vaccine could be a novel immunotherapeutic agent against ATLL. According to the original protocol, patients received a biweekly administration of varicella vaccine. In this retrospective study, 33 patients were recruited in our institute between March 2002 and December 2010. All patients with a previously untreated and histology proven ATLL were eligible for the purpose of the study. Complete response lasting for six months or more was seen in 6 (18%), partial response in 2 (6%), and no response in 7 (21%) patients, with a median follow-up duration of 27 months (range, 6-99 months). The median overall survival was 24 months and this was significantly longer compared to previously reported f indings (16 months). No serious adverse events were observed. In conclusion, smoldering ATLL with the skin lesions and cutaneous ATLL are promising candidates for this varicella vaccine immunotherapy.

Authors’ Affiliations

(1)
Department of Dermatology, University of Miyazaki, Kiyotake, Miyazaki, Japan

Copyright

© Amano and Setoyama; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement